Anti-interleukin-6 receptor antibody treatment ameliorates postoperative adhesion formation

被引:0
|
作者
Naoki Uyama
Hiroko Tsutsui
Songtao Wu
Koubun Yasuda
Etsuro Hatano
Xian-Yang Qin
Soichi Kojima
Jiro Fujimoto
机构
[1] Hyogo College of Medicine,Department of Surgery
[2] Nishinomiya,Department of Immunology
[3] Hyogo College of Medicine,Liver Cancer Prevention Research Unit
[4] Nishinomiya,undefined
[5] RIKEN Center for Integrative Medical Sciences,undefined
[6] Wako,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Postoperative adhesion formation often ruins the quality of life or is an obstacle to illnesses with curative operation such as cancer. Previously we demonstrated that interferon-γ-promoted fibrin deposition drove postoperative adhesion formation. However, its underlying cellular and molecular mechanisms remain poorly understood. We found that myofibroblasts of the adhesion predominantly expressed signature molecules of mesothelial cells that line the serosa. Microarray analysis revealed IL-6 as a key underlying player, supported by elevated IL-6 levels in the peritoneal fluid of post-laparotomy human subjects. Injured serosa of cecum-cauterized mice also exhibited induction of Il6, which was followed by Tnf, concomitant with rapid accumulation of neutrophils, substantial population of which expressed TGF-β1, a master regulator of fibrosis. Besides, neutrophil-ablated mice showed reduction in induction of the adhesion, suggesting that TGF-β1+neutrophils triggered the adhesion. Human neutrophils expressed TGFB1 in response to TNF-α and TNF in response to IL-6. Moreover, anti-IL-6 receptor monoclonal antibody abrogated neutrophil recruitment and adhesion formation. Thus, IL-6 signaling represents a potential target for the prevention of postoperative adhesions.
引用
收藏
相关论文
共 50 条
  • [41] SENSITIZATION OF HUMAN RENAL-CELL CARCINOMA-CELLS TO CIS-DIAMINEDICHLOROPLATINUM(II) BY ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY OR ANTI-INTERLEUKIN-6 RECEPTOR MONOCLONAL-ANTIBODY
    MIZUTANI, Y
    BONAVIDA, B
    KOISHIHARA, Y
    AKAMATSU, K
    OHSUGI, Y
    YOSHIDA, O
    CANCER RESEARCH, 1995, 55 (03) : 590 - 596
  • [42] Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab
    Tanaka, Toshio
    Hagihara, Keisuke
    Shima, Yoshihito
    Narazaki, Masashi
    Ogata, Atsushi
    Kawase, Ichiro
    Kishimoto, Tadamitsu
    RHEUMATOLOGY, 2010, 49 (04) : 824 - 826
  • [43] Tocilizumab, An Anti-Interleukin-6 Receptor Antibody For The Treatment Of Multicentric Castleman's Disease With Pulmonary Involvement: A Case Study
    Amano, M.
    Nishizawa, T.
    Ohba, T.
    Honda, K.
    Okuda, R.
    Matsushima, H.
    Takemura, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [44] Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy
    Yuzuriha, Akinori
    Saitoh, Takayuki
    Koiso, Hiromi
    Mitsui, Takeki
    Uchiumi, Hideki
    Yokohama, Akihiko
    Handa, Hiroshi
    Kojima, Masaru
    Tsukamoto, Norifumi
    Karaswa, Masamitsu
    Murakami, Hirokazu
    Nojima, Yoshihisa
    ACTA HAEMATOLOGICA, 2011, 126 (03) : 147 - 150
  • [45] Successful treatment of multicentric Castleman's disease associated with dystrophic epidermolysis bullosa using anti-interleukin-6 receptor antibody
    Naruse, Satsuki
    Takashima, Shota
    Fujita, Yasuyuki
    Kataoka, Hiroshi
    Kawamura, Nobuaki
    Natsuga, Ken
    Ujiie, Hideyuki
    JOURNAL OF DERMATOLOGY, 2024, 51 (08): : e268 - e269
  • [46] Anti-interleukin-6 receptor antibody reduces neuropathic pain following spinal cord injury in mice
    Murakami, Tomotoshi
    Kanchiku, Tsukasa
    Suzuki, Hidenori
    Imajo, Yasuaki
    Yoshida, Yuichiro
    Nomura, Hiroshi
    Cui, Dan
    Ishikawa, Toshizo
    Ikeda, Eiji
    Taguchi, Toshihiko
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 6 (05) : 1194 - 1198
  • [47] Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
    Kawashiri, Shin-ya
    Kawakami, Atsushi
    Yamasaki, Satoshi
    Imazato, Takahiro
    Iwamoto, Naoki
    Fujikawa, Keita
    Aramaki, Toshiyuki
    Tamai, Mami
    Nakamura, Hideki
    Ida, Hiroaki
    Origuchi, Tomoki
    Ueki, Yukitaka
    Eguchi, Katsumi
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (04) : 451 - 456
  • [48] Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody
    Noriyuki Nishiwaki
    Kazuhiro Noma
    Toshiaki Ohara
    Tomoyoshi Kunitomo
    Kento Kawasaki
    Masaaki Akai
    Teruki Kobayashi
    Toru Narusaka
    Hajime Kashima
    Hiroaki Sato
    Satoshi Komoto
    Takuya Kato
    Naoaki Maeda
    Satoru Kikuchi
    Shunsuke Tanabe
    Hiroshi Tazawa
    Yasuhiro Shirakawa
    Toshiyoshi Fujiwara
    Cancer Immunology, Immunotherapy, 2023, 72 : 2029 - 2044
  • [49] ANTI-INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    EVANS, M
    ABDOU, NI
    LUPUS, 1994, 3 (03) : 161 - 166
  • [50] Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever
    Hamanoue, Satoshi
    Suwabe, Tatsuya
    Hoshino, Junichi
    Sumida, Keiichi
    Mise, Koki
    Hayami, Noriko
    Sawa, Naoki
    Takaichi, Kenmei
    Fujii, Takeshi
    Ohashi, Kenichi
    Yazaki, Masahide
    Ikeda, Shuichi
    Ubara, Yoshifumi
    MODERN RHEUMATOLOGY, 2016, 26 (04) : 610 - 613